Stocks and Investing
Stocks and Investing
Fri, March 23, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, March 22, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 21, 2018
Matthew Harrison Maintained (BLUE) at Hold with Increased Target to $209 on, Mar 21st, 2018
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Increased Target from $152 to $209 on, Mar 21st, 2018.
Matthew has made no other calls on BLUE in the last 4 months.
There are 7 other peers that have a rating on BLUE. Out of the 7 peers that are also analyzing BLUE, 4 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $218 on, Thursday, February 22nd, 2018
- Michael Schmidt of "Leerink Swann" Downgraded from Buy to Hold on, Thursday, January 25th, 2018
- Mark Breidenbach of "Oppenheimer" Initiated at Hold on, Thursday, December 21st, 2017
- Jason McCarthy of "Maxim Group" Downgraded from Strong Buy to Hold on, Wednesday, December 13th, 2017
These are the ratings of the 3 analyists that currently disagree with Matthew
- Matthew Luchini of "BMO Capital" Maintained at Buy with Increased Target to $222 on, Thursday, February 22nd, 2018
- Biren Amin of "Jefferies" Upgraded from Hold to Strong Buy on, Monday, December 11th, 2017
- John Newman of "Canaccord Genuity" Initiated at Strong Buy and Held Target at $202 on, Tuesday, December 5th, 2017